Par Drugs (India) Performance
| PAR Stock | 290.40 11.35 4.07% |
On a scale of 0 to 100, Par Drugs holds a performance score of 6. The company holds a Beta of 0.0772, which implies not very significant fluctuations relative to the market. As returns on the market increase, Par Drugs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Par Drugs is expected to be smaller as well. Please check Par Drugs' skewness, day typical price, and the relationship between the downside variance and daily balance of power , to make a quick decision on whether Par Drugs' historical price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Par Drugs And are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak technical and fundamental indicators, Par Drugs exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 2:1 | Ex Dividend Date 2021-11-22 | Last Split Date 2021-04-27 |
1 | Is Par Drugs and Chemicals Limiteds Recent Stock Performance Tethered To Its Strong Fundamentals - Simply Wall St | 10/17/2024 |
2 | Breakout stocks to buy or sell FSL to Indian Bank Sumeet Bagadia recommends five shares to buy today Stock Market News - Mint | 10/29/2024 |
| Begin Period Cash Flow | 222.4 M |
Par |
Par Drugs Relative Risk vs. Return Landscape
If you would invest 24,920 in Par Drugs And on September 1, 2024 and sell it today you would earn a total of 4,120 from holding Par Drugs And or generate 16.53% return on investment over 90 days. Par Drugs And is generating 0.3194% of daily returns and assumes 4.0533% volatility on return distribution over the 90 days horizon. Simply put, 36% of stocks are less volatile than Par, and 94% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Par Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Par Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Par Drugs And, and traders can use it to determine the average amount a Par Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0788
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PAR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.05 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.32 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Par Drugs is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Par Drugs by adding it to a well-diversified portfolio.
Par Drugs Fundamentals Growth
Par Stock prices reflect investors' perceptions of the future prospects and financial health of Par Drugs, and Par Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Par Stock performance.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 3.25 B | ||||
| Shares Outstanding | 12.3 M | ||||
| Price To Book | 3.55 X | ||||
| Price To Sales | 3.34 X | ||||
| Revenue | 956.4 M | ||||
| Gross Profit | 457.57 M | ||||
| EBITDA | 229.53 M | ||||
| Net Income | 145.01 M | ||||
| Total Debt | 159.79 M | ||||
| Book Value Per Share | 78.69 X | ||||
| Cash Flow From Operations | 202.49 M | ||||
| Earnings Per Share | 14.85 X | ||||
| Total Asset | 1.02 B | ||||
| Retained Earnings | 625.51 M | ||||
About Par Drugs Performance
By analyzing Par Drugs' fundamental ratios, stakeholders can gain valuable insights into Par Drugs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Par Drugs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Par Drugs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Par Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Par Drugs And performance evaluation
Checking the ongoing alerts about Par Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Par Drugs And help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Par Drugs And had very high historical volatility over the last 90 days | |
| Par Drugs And is unlikely to experience financial distress in the next 2 years |
- Analyzing Par Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Par Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Par Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Par Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Par Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Par Drugs' stock. These opinions can provide insight into Par Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Par Stock analysis
When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |